drugset / Trial / NCT01897116

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

NCT01897116

Phase 1 Completed 8 enrolled Abramson Cancer Center at Penn Medicine
NaSingle-groupSingle-blindTreatment

Summary

This is a Phase I study combining vemurafenib and hydroxychloroquine in the treatment of BRAF V600E+ metastatic melanoma.

Timeline

Start
2013-06
Primary completion
2016-07-12
Completion
2016-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule
Subject Vemurafenib Small molecule

Indications